Development and Validation of a Prognostic Clinical Risk Score for Subsequent Atopic Dermatitis Risk

IF 6.3 2区 医学 Q1 ALLERGY Clinical and Experimental Allergy Pub Date : 2024-09-24 DOI:10.1111/cea.14567
Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev, Oliver Sanders, Shira Benor, Michael Brandwein
{"title":"Development and Validation of a Prognostic Clinical Risk Score for Subsequent Atopic Dermatitis Risk","authors":"Tamar Landau,&nbsp;Keren Gamrasni,&nbsp;Alex Levin,&nbsp;Yotam Barlev,&nbsp;Oliver Sanders,&nbsp;Shira Benor,&nbsp;Michael Brandwein","doi":"10.1111/cea.14567","DOIUrl":null,"url":null,"abstract":"<p>Atopic dermatitis (AD), is a common, complex and heterogeneous inflammatory skin disease [<span>1</span>]. Many patients develop AD by 5 years, directly affecting quality of life [<span>2</span>], and increasing risk for other comorbidities, including asthma, allergic rhinitis, and food allergies [<span>3</span>]. Filaggrin mutations and family history of atopy are important risk factors for AD development [<span>1, 4</span>]. Each provides poor predictive value when used independently to stratify risk, yet family history of atopy has been used in the research setting [<span>5, 6</span>] and is the current standard of care (SOC). A prognostic AD clinical risk score can empower clinicians to diagnose AD earlier on. It can also be employed by the clinical trialist to enrich birth cohorts with a priori screening for at-risk patients. We aimed to develop a clinical risk score using information available in the prenatal period, with consideration to explainability and applicability, and validate it on an external, geographically independent dataset.</p><p>The training dataset included the electronic medical records (EMR) of all infant-mother dyads captured in the Leumit Health Services (Leumit) EMR between 2010 and 2019 with a recorded AD diagnosis before the age of three (<i>n</i> = 7370) and a random sample of infant-mother dyads selected from the Leumit EMR whereby AD was not diagnosed in the child's EMR (<i>n</i> = 63,852). Leumit is one of four national health providers and its EMR captures routine data from all medical consultations, procedures, and prescriptions, along with relevant sociodemographic data. The US-based Infant Feeding Practices Study 2 (IFPS2) was used as a validation dataset [<span>7</span>]. The cohort included a nationally distributed panel of 1807 infants born between 2005 and 2007, of which 389 (21.5%) reported a doctor's diagnosis of AD by the age of one. Additional information about study methods and findings are available in the online repository (https://github.com/tami-myor/AD-Score/tree/main).</p><p>The scoring method is designed to generate a value from 0 to 1, representing the probable risk in probabilistic terms, and can be effectively calculated if some variables are missing. Patients were divided into high (&gt; 0.5), medium (0.35–0.5) and low-risk groups (&lt; 0.35) There was a significant difference in means among the risk groups in relation to the actual cases of atopic dermatitis (ANOVA, <i>p</i> &lt; 0.001) for both train and validation set. When compared to the SOC, individuals in the low-risk group were less likely to develop AD than those without a parental history of atopy and individuals in the high-risk group were more likely to develop AD than those with a parental history of atopy for both train and validation set. The OR in a univariate logistic regression model for developing AD was 2.30 (CI 2.15–2.46, <i>p</i> &lt; 0.001) for the medium-risk group and 4.06 (CI 3.80–4.34, <i>p</i> &lt; 0.001) for the high-risk group when compared with the low-risk group in the training dataset. Separately, the OR for developing AD was 1.74 (CI 1.34–2.27, <i>p</i> &lt; 0.001) for the medium-risk group and 3.36 (CI 2.51–4.49, <i>p</i> &lt; 0.001) for the high-risk group when compared with the low-risk group in the validation dataset. These high-risk ORs are more than double the OR of the SOC parental history of atopy calculated in the original multivariate model (OR 1.57, CI 1.43–1.72, <i>p</i> &lt; 0.001) and demonstrate the utility of this method over the current SOC.</p><p>This prognostic AD risk assessment model harnesses known environmental and familial associations into a quantifiable and applicable clinical tool. It holds the potential to inform clinicians and caregivers as to an infant's risk of developing AD thereby influencing the continuum of care, enabling earlier diagnosis, and targeting patients to adopt preventive measures for other atopic conditions. Furthermore, it can reduce cohort sizes for AD-prevention clinical trials. While developed on epidemiological data from an EMR, the validation study showed its applicability on a geographically distinct survey-based cohort, thereby opening the door to deployment in a variety of settings. An important limitation in the validation dataset is its inclusion of diagnoses until 1 year of age, as opposed to 3 years of age in the development dataset. Undoubtedly, the inclusion of genetic information would further buttress the predictive capability of the model. Future studies can further this approach by incorporating additional documented risk factors and by exploring the utility of this approach for other conditions associated with the atopic march.</p><p><b>Tamar Landau:</b> data curation (supporting), formal analysis (lead), investigation (supporting), writing – review &amp; editing (equal). <b>Keren Gamrasni:</b> project administration (supporting), investigation (supporting), writing – review &amp; editing (equal). <b>Alex Levin:</b> project administration (supporting), investigation (supporting), writing – review &amp; editing (equal). <b>Yotam Barlev:</b> project administration (supporting), investigation (supporting), writing – review &amp; editing (equal). <b>Oliver Sanders:</b> resources (equal), supervision (equal), investigation (supporting), writing – review &amp; editing (equal). <b>Shira Benor:</b> resources (equal), supervision (equal), investigation (supporting), writing – review &amp; editing (equal). <b>Michael Brandwein:</b> conceptualization (lead), data curation (supporting), formal analysis (supporting), investigation (lead), project administration (supporting), writing – original draft preparation (lead).</p><p>This study was performed according to the approved protocols and procedures received from the Helsinki Committee of Leumit Healthcare Services, Israel (October 2022, approval number 0026-22-LEU). A written informed consent waiver was obtained by the Helsinki committee based on the nature of the study, specifically the use of deidentified and previously collected data.</p><p>Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev and Michael Brandwein report personal fees from MYOR Diagnostics Ltd., during the conduct of the study. MYOR Diagnostics Ltd. develops innovative, evidence-based educational tools designed to help parents and clinicians understand and manage a child's health from the earliest stages of life. The company does not have any intellectual property related to the model described in this manuscript.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 2","pages":"190-192"},"PeriodicalIF":6.3000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14567","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cea.14567","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Atopic dermatitis (AD), is a common, complex and heterogeneous inflammatory skin disease [1]. Many patients develop AD by 5 years, directly affecting quality of life [2], and increasing risk for other comorbidities, including asthma, allergic rhinitis, and food allergies [3]. Filaggrin mutations and family history of atopy are important risk factors for AD development [1, 4]. Each provides poor predictive value when used independently to stratify risk, yet family history of atopy has been used in the research setting [5, 6] and is the current standard of care (SOC). A prognostic AD clinical risk score can empower clinicians to diagnose AD earlier on. It can also be employed by the clinical trialist to enrich birth cohorts with a priori screening for at-risk patients. We aimed to develop a clinical risk score using information available in the prenatal period, with consideration to explainability and applicability, and validate it on an external, geographically independent dataset.

The training dataset included the electronic medical records (EMR) of all infant-mother dyads captured in the Leumit Health Services (Leumit) EMR between 2010 and 2019 with a recorded AD diagnosis before the age of three (n = 7370) and a random sample of infant-mother dyads selected from the Leumit EMR whereby AD was not diagnosed in the child's EMR (n = 63,852). Leumit is one of four national health providers and its EMR captures routine data from all medical consultations, procedures, and prescriptions, along with relevant sociodemographic data. The US-based Infant Feeding Practices Study 2 (IFPS2) was used as a validation dataset [7]. The cohort included a nationally distributed panel of 1807 infants born between 2005 and 2007, of which 389 (21.5%) reported a doctor's diagnosis of AD by the age of one. Additional information about study methods and findings are available in the online repository (https://github.com/tami-myor/AD-Score/tree/main).

The scoring method is designed to generate a value from 0 to 1, representing the probable risk in probabilistic terms, and can be effectively calculated if some variables are missing. Patients were divided into high (> 0.5), medium (0.35–0.5) and low-risk groups (< 0.35) There was a significant difference in means among the risk groups in relation to the actual cases of atopic dermatitis (ANOVA, p < 0.001) for both train and validation set. When compared to the SOC, individuals in the low-risk group were less likely to develop AD than those without a parental history of atopy and individuals in the high-risk group were more likely to develop AD than those with a parental history of atopy for both train and validation set. The OR in a univariate logistic regression model for developing AD was 2.30 (CI 2.15–2.46, p < 0.001) for the medium-risk group and 4.06 (CI 3.80–4.34, p < 0.001) for the high-risk group when compared with the low-risk group in the training dataset. Separately, the OR for developing AD was 1.74 (CI 1.34–2.27, p < 0.001) for the medium-risk group and 3.36 (CI 2.51–4.49, p < 0.001) for the high-risk group when compared with the low-risk group in the validation dataset. These high-risk ORs are more than double the OR of the SOC parental history of atopy calculated in the original multivariate model (OR 1.57, CI 1.43–1.72, p < 0.001) and demonstrate the utility of this method over the current SOC.

This prognostic AD risk assessment model harnesses known environmental and familial associations into a quantifiable and applicable clinical tool. It holds the potential to inform clinicians and caregivers as to an infant's risk of developing AD thereby influencing the continuum of care, enabling earlier diagnosis, and targeting patients to adopt preventive measures for other atopic conditions. Furthermore, it can reduce cohort sizes for AD-prevention clinical trials. While developed on epidemiological data from an EMR, the validation study showed its applicability on a geographically distinct survey-based cohort, thereby opening the door to deployment in a variety of settings. An important limitation in the validation dataset is its inclusion of diagnoses until 1 year of age, as opposed to 3 years of age in the development dataset. Undoubtedly, the inclusion of genetic information would further buttress the predictive capability of the model. Future studies can further this approach by incorporating additional documented risk factors and by exploring the utility of this approach for other conditions associated with the atopic march.

Tamar Landau: data curation (supporting), formal analysis (lead), investigation (supporting), writing – review & editing (equal). Keren Gamrasni: project administration (supporting), investigation (supporting), writing – review & editing (equal). Alex Levin: project administration (supporting), investigation (supporting), writing – review & editing (equal). Yotam Barlev: project administration (supporting), investigation (supporting), writing – review & editing (equal). Oliver Sanders: resources (equal), supervision (equal), investigation (supporting), writing – review & editing (equal). Shira Benor: resources (equal), supervision (equal), investigation (supporting), writing – review & editing (equal). Michael Brandwein: conceptualization (lead), data curation (supporting), formal analysis (supporting), investigation (lead), project administration (supporting), writing – original draft preparation (lead).

This study was performed according to the approved protocols and procedures received from the Helsinki Committee of Leumit Healthcare Services, Israel (October 2022, approval number 0026-22-LEU). A written informed consent waiver was obtained by the Helsinki committee based on the nature of the study, specifically the use of deidentified and previously collected data.

Tamar Landau, Keren Gamrasni, Alex Levin, Yotam Barlev and Michael Brandwein report personal fees from MYOR Diagnostics Ltd., during the conduct of the study. MYOR Diagnostics Ltd. develops innovative, evidence-based educational tools designed to help parents and clinicians understand and manage a child's health from the earliest stages of life. The company does not have any intellectual property related to the model described in this manuscript.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
开发并验证特应性皮炎后续风险的临床预后风险评分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
Rapamycin mitigates erythrocyte membrane transport functions and oxidative stress during aging in rats.
IF 3 4区 医学Archives of Physiology and BiochemistryPub Date : 2018-02-01 DOI: 10.1080/13813455.2017.1359629
Abhishek Kumar Singh, Sandeep Singh, Geetika Garg, Syed Ibrahim Rizvi
Hormetic effect of 3-Bromopyruvate on age-induced alterations in erythrocyte membrane transporters and oxidative biomarkers in rats.
IF 2.6 4区 医学Rejuvenation researchPub Date : 2022-04-04 DOI: 10.1089/rej.2021.0060
J. Arya, Raushan Kumar, Shambhoo Sharan Tripathi, S. Rizvi
来源期刊
CiteScore
10.40
自引率
9.80%
发文量
189
审稿时长
3-8 weeks
期刊介绍: Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field. In response to the increasing number of quality submissions, since 1996 the journals size has increased by over 30%. Clinical & Experimental Allergy is essential reading for allergy practitioners and research scientists with an interest in allergic diseases and mechanisms. Truly international in appeal, Clinical & Experimental Allergy publishes clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.
期刊最新文献
Clinical Presentation and Nutrition Management of Non-IgE-Mediated Food Allergy in Children. Eosinophilic Oesophagitis in Adults: National Centre Retrospective Study in an Irish Cohort. Prevalence and Clinical Symptoms of Wheat Allergy in Adults and Adolescents in Central Europe. Th2-Polarised CD4+ T Cells Enhance Staphylococcus aureus Growth in a 3D Skin Model. Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK-air Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1